Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2016-2025

ABSTRACT

The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group [NCI-ODWG] criteria for hepatic dysfunction. Detailed Description Hepatic impairment is a common co-morbidity in cancer patients, particularly in those with extensive liver metastases. Decreased drug clearance as a result of impaired liver function may lead to increased systemic exposure and possibly greater toxicity. As many chemotherapeutic agents are metabolized by the liver, treatment options tend to be limited in patients with severe hepatic impairment, even in the presence of good performance status and adequate other organ function. Cisplatin is an active chemotherapeutic agent with broad spectrum activity that can safely be administered in severe hepatic impairment. Cisplatin has been combined safely with full dose oral TS-1 with good efficacy in a spectrum of solid tumors in patients with adequate renal and hepatic function. The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group [NCI-ODWG] criteria for hepatic dysfunction. More... »

URL

https://clinicaltrials.gov/show/NCT03519074

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group [NCI-ODWG] criteria for hepatic dysfunction.\n\nDetailed Description\nHepatic impairment is a common co-morbidity in cancer patients, particularly in those with extensive liver metastases. Decreased drug clearance as a result of impaired liver function may lead to increased systemic exposure and possibly greater toxicity. As many chemotherapeutic agents are metabolized by the liver, treatment options tend to be limited in patients with severe hepatic impairment, even in the presence of good performance status and adequate other organ function. Cisplatin is an active chemotherapeutic agent with broad spectrum activity that can safely be administered in severe hepatic impairment. Cisplatin has been combined safely with full dose oral TS-1 with good efficacy in a spectrum of solid tumors in patients with adequate renal and hepatic function. The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group [NCI-ODWG] criteria for hepatic dysfunction.", 
    "endDate": "2025-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03519074", 
    "keywords": [
      "Phase II", 
      "cisplatin", 
      "in-patient", 
      "advanced solid tumor", 
      "different degree", 
      "pharmacokinetics", 
      "PK", 
      "safety", 
      "tolerability", 
      "adult patient", 
      "impairment", 
      "patient", 
      "hepatic function", 
      "National Cancer Institute", 
      "organ dysfunction", 
      "criterion", 
      "hepatic dysfunction", 
      "common co-morbidity", 
      "cancer patient", 
      "liver metastasis", 
      "drug clearance", 
      "liver function", 
      "systemic exposure", 
      "toxicity", 
      "chemotherapeutic agent", 
      "liver", 
      "treatment option", 
      "performance status", 
      "organ function", 
      "broad spectrum activity", 
      "full dose", 
      "good efficacy", 
      "spectrum", 
      "solid tumor"
    ], 
    "name": "Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03519074"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00027.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.412106.0", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.459815.4", 
        "type": "Organization"
      }
    ], 
    "startDate": "2016-07-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1097/00001813-200402000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010488662"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00411-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011227116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2738-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017964093", 
          "https://doi.org/10.1007/s00280-015-2738-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03519074"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03519074'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03519074'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03519074'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03519074'


 

This table displays all metadata directly associated to this object as RDF triples.

65 TRIPLES      16 PREDICATES      53 URIs      43 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03519074 schema:about anzsrc-for:3053
2 schema:description The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group [NCI-ODWG] criteria for hepatic dysfunction. Detailed Description Hepatic impairment is a common co-morbidity in cancer patients, particularly in those with extensive liver metastases. Decreased drug clearance as a result of impaired liver function may lead to increased systemic exposure and possibly greater toxicity. As many chemotherapeutic agents are metabolized by the liver, treatment options tend to be limited in patients with severe hepatic impairment, even in the presence of good performance status and adequate other organ function. Cisplatin is an active chemotherapeutic agent with broad spectrum activity that can safely be administered in severe hepatic impairment. Cisplatin has been combined safely with full dose oral TS-1 with good efficacy in a spectrum of solid tumors in patients with adequate renal and hepatic function. The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group [NCI-ODWG] criteria for hepatic dysfunction.
3 schema:endDate 2025-12-01T00:00:00Z
4 schema:keywords National Cancer Institute
5 PK
6 Phase II
7 adult patient
8 advanced solid tumor
9 broad spectrum activity
10 cancer patient
11 chemotherapeutic agent
12 cisplatin
13 common co-morbidity
14 criterion
15 different degree
16 drug clearance
17 full dose
18 good efficacy
19 hepatic dysfunction
20 hepatic function
21 impairment
22 in-patient
23 liver
24 liver function
25 liver metastasis
26 organ dysfunction
27 organ function
28 patient
29 performance status
30 pharmacokinetics
31 safety
32 solid tumor
33 spectrum
34 systemic exposure
35 tolerability
36 toxicity
37 treatment option
38 schema:name Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction
39 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03519074
40 schema:sdDatePublished 2019-03-07T15:27
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N97fe7efce0934cdf8086e0436edfb947
43 schema:sponsor https://www.grid.ac/institutes/grid.412106.0
44 https://www.grid.ac/institutes/grid.459815.4
45 schema:startDate 2016-07-01T00:00:00Z
46 schema:subjectOf sg:pub.10.1007/s00280-015-2738-3
47 https://doi.org/10.1016/s1470-2045(15)00411-8
48 https://doi.org/10.1097/00001813-200402000-00001
49 schema:url https://clinicaltrials.gov/show/NCT03519074
50 sgo:license sg:explorer/license/
51 sgo:sdDataset clinical_trials
52 rdf:type schema:MedicalStudy
53 N97fe7efce0934cdf8086e0436edfb947 schema:name Springer Nature - SN SciGraph project
54 rdf:type schema:Organization
55 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
56 rdf:type schema:DefinedTerm
57 sg:pub.10.1007/s00280-015-2738-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017964093
58 https://doi.org/10.1007/s00280-015-2738-3
59 rdf:type schema:CreativeWork
60 https://doi.org/10.1016/s1470-2045(15)00411-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011227116
61 rdf:type schema:CreativeWork
62 https://doi.org/10.1097/00001813-200402000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010488662
63 rdf:type schema:CreativeWork
64 https://www.grid.ac/institutes/grid.412106.0 schema:Organization
65 https://www.grid.ac/institutes/grid.459815.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...